loading
Vistagen Therapeutics Inc stock is traded at $2.55, with a volume of 188.93K. It is up +0.00% in the last 24 hours and up +27.50% over the past month. Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$2.55
Open:
$2.55
24h Volume:
188.93K
Relative Volume:
0.93
Market Cap:
$74.35M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-1.8997
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
+13.33%
1M Performance:
+27.50%
6M Performance:
-14.72%
1Y Performance:
-34.95%
1-Day Range:
Value
$2.50
$2.5891
1-Week Range:
Value
$2.27
$2.6732
52-Week Range:
Value
$1.90
$4.01

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
Name
Vistagen Therapeutics Inc
Name
Phone
650-577-3600
Name
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
Employee
57
Name
Twitter
@vistagen
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
VTGN's Discussions on Twitter

Compare VTGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.55 69.40M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.52 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
556.41 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.30 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
573.50 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.38 27.29B 3.81B -644.79M -669.77M -6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-07-23 Upgrade Jefferies Hold → Buy
Aug-07-23 Upgrade Maxim Group Hold → Buy
Jul-22-22 Downgrade Jefferies Buy → Hold
Jul-22-22 Downgrade Robert W. Baird Outperform → Neutral
Jul-22-22 Downgrade William Blair Outperform → Mkt Perform
May-20-21 Initiated Robert W. Baird Outperform
Feb-18-21 Initiated Jefferies Buy
Jan-04-21 Upgrade William Blair Mkt Perform → Outperform
Jun-27-18 Initiated Maxim Group Buy
Feb-08-18 Reiterated Chardan Capital Markets Buy
Mar-28-17 Initiated Maxim Group Buy
View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

pulisher
08:24 AM

Vistagen Therapeutics Inc. Stock Analysis and ForecastExplosive earnings growth - jammulinksnews.com

08:24 AM
pulisher
Jul 21, 2025

What analysts say about Vistagen Therapeutics Inc. stockAccelerated investment success - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Is Vistagen Therapeutics Inc. a good long term investmentHigh-velocity capital appreciation - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat

Jul 19, 2025
pulisher
Jul 19, 2025

What drives Vistagen Therapeutics Inc. stock priceRapid wealth accumulation - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Is Vistagen Therapeutics Inc. stock a good hedge against inflationHigh Confidence Trade Setups - beatles.ru

Jul 18, 2025
pulisher
Jul 15, 2025

How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Vistagen Therapeutics Inc. stock price move sharplyFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan

Jul 15, 2025
pulisher
Jul 13, 2025

Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com

Jul 13, 2025
pulisher
Jul 11, 2025

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN

Jul 11, 2025
pulisher
Jun 26, 2025

Research Analysts Set Expectations for VTGN Q1 Earnings - MarketBeat

Jun 26, 2025
pulisher
Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria

Jun 25, 2025
pulisher
Jun 25, 2025

Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com

Jun 25, 2025
pulisher
Jun 23, 2025

William Blair Issues Negative Forecast for VTGN Earnings - Defense World

Jun 23, 2025
pulisher
Jun 22, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - Insider Monkey

Jun 22, 2025
pulisher
Jun 21, 2025

William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat

Jun 21, 2025
pulisher
Jun 20, 2025

Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest

Jun 20, 2025
pulisher
Jun 19, 2025

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Jun 19, 2025
pulisher
Jun 19, 2025

VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo News Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise

Jun 17, 2025
pulisher
Jun 17, 2025

Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassi - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen (VTGN) Reports Decrease in FY25 Revenue, Advances Key Medical Programs | VTGN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen Therapeutics, Inc. SEC 10-K Report - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Vistagen to Report Fiscal Year 2025 Financial Results and Host C - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus

Jun 16, 2025

Vistagen Therapeutics Inc Stock (VTGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 0.54%
$35.88
price up icon 0.63%
$103.33
price up icon 0.72%
$26.39
price up icon 0.15%
$109.96
price up icon 0.27%
biotechnology ONC
$294.38
price up icon 0.90%
Cap:     |  Volume (24h):